Update multiple endocrine neoplasia type 2.

Area of Science:

• Genetics
• Oncology
• Endocrinology

Background:

• Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant inherited tumor syndrome.
• It arises from germline activating mutations in the RET proto-oncogene.
• MEN2 manifests in distinct clinical forms: MEN 2A, MEN 2B, and familial MTC (FMTC).

Purpose of the Study:

• To elucidate the genetic basis and clinical spectrum of MEN2.
• To highlight the importance of genetic testing for early diagnosis and management.
• To establish genotype-phenotype correlations for risk stratification and treatment planning.

Main Methods:

• Germline DNA analysis to detect RET proto-oncogene mutations.
• Clinical evaluation of patients for characteristic MEN2 phenotypes.
• Correlation of specific RET mutations with clinical manifestations and disease risk.

Main Results:

• Specific RET gene mutations are associated with distinct MEN2 variants (MEN 2A, MEN 2B, FMTC).
• Genetic testing achieves nearly 100% detection of mutation carriers.
• Strong genotype-phenotype correlations guide risk assessment and management strategies.

Conclusions:

• MEN2 serves as a model for cancer prevention through mutation-based carrier diagnosis.
• Prophylactic thyroidectomy timing and surgical extent are determined by genotype-based risk stratification.
• Personalized, mutation-driven approaches offer opportunities for early intervention and improved outcomes in MEN2.